Making the Way for Innovation

(W1) Evaluating the Evidence of Prescription Digital Therapeutics: A Panel Discussion

Wednesday, March 22, 2023

8:45 AM – 10:00 AM

Location: B2/3

ACPE UAN:0233-0000-23-024-L99-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Joseph A. Albright, PharmD

Director, Commercial Pharmacy Programs
Blue Cross Blue Shield North Carolina
Durham, NC
Terry Cothran, DPh

Senior Pharmacy Director
Oklahoma Health Care Authority
Oklahoma City,, OK
Sam Sui, PharmD (he/him/his)

Utilization Management Clinical Pharmacist
Fallon Health
Worcester, MA

Moderator(s)

Joseph Honcz, RPh MBA (he/him/his)

President
C4i
Milford, CT

The role of digital therapeutics (DTx) in preventing, managing, and treating medical conditions continues to evolve. With advancement comes opportunities but also challenges. Payers must be able to make informed and consistent DTx coverage decisions, making sure the evaluation of DTx products includes evidence that demonstrates a DTx product improves quality of care.

Whether prescription digital therapeutic (PDT) or non-prescription, how are DTx coverage and reimbursement decisions being made? More importantly, what data is being evaluated, and how? In this session, you will learn how DTx has evolved, as well as hear from various health plans as they highlight what considerations go into their data collection and evaluation of PDTs.

Learning Objectives::

At the completion of this activity, participants should be able to:

Describe the landscape and evolution of DTx.
Discuss what data is currently being evaluated prior to PDT coverage considerations.
Identify what data may still be desired for payers to make an informed and consistent coverage decision for PDTs.
Discuss how the evaluation process for a PDT differs from that of a drug.